Visit Us at Booth 539

Discover the impact
of the world's largest clinico-genomic study
of canine cancer

Come meet the authors of the 

World’s Largest Clinico-Genomics Study of Canine Cancer

at the ACVIM Forum in Philadelphia, Pennsylvania

from June 15-17

Cancer is the leading cause of death in dogs, yet canine cancer care is decades behind that of humans. That’s why FidoCure® is proud to have conducted the world’s largest clinico-genomic canine cancer study in partnership with Stanford AI Health. The study, published in the esteemed Nature Precision Oncology Journal is peer-reviewed and is the only one of its kind with outcomes. It has revealed a promising new path towards enhanced human cancer treatments while also helping veterinarians in their clinics today.

The outcomes from this study can be used in veterinary practice today. Our research has shown that genotyping matters- knowing which genes are mutated can tell us something about a dog’s prognosis immediately. By studying 2,119 dogs with cancer from over 200 veterinary clinics, we have confirmed the similarities between human and canine cancer journeys and revealed new applications for existing human cancer treatments.

With our study, we are bringing human-standard precision medicine of the 21st century to dog patients. By treating our canine family members, we are simultaneously advancing the discovery of new therapeutics for human cancer. Our goal is to turn every veterinarian in the US into a protagonist in the future of cancer care.

Read press coverage of our latest peer-reviewed paper:

Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs

Despite a growing number of targeted cancer treatments in development each year, few are able to reach cancer patients due to the rate at which evidence is generated from human clinical trials. As such, complementary models for cancer are necessary to effectively move from preclinical investigations to clinical translation. In particular, spontaneous tumors in canines are valuable sources of evidence for understanding human cancers, with one in three dogs developing cancer within their lifetime.

Dogs and humans share similar environments, nutrition, intact immune systems, cancer histology, therapeutic response, acquired resistance, recurrence, metastasis, and genetic and molecular targets


Could Fido lead us to better cancer drugs?

A recent study offers up a trove of data on dog cancer health outcomes from targeted therapies that could help improve care for people.



World’s largest genomic study of canine cancer reveals potential for novel human cancer treatments

Researchers from Stanford AI Health and One Health, the world’s first translational canine cancer care company, published the results from the largest-ever genomic study of canine cancer which revealed a promising path for enhanced human cancer treatments.


Your Dog Is a Secret Weapon in the Fight Against Cancer

Every year, thousands of pets develop tumors very similar to those found in people. Find drugs that work for canines, and human treatments should follow.


As Seen On